Literature DB >> 33727921

Circulating Exosomal miR-96 as a Novel Biomarker for Radioresistant Non-Small-Cell Lung Cancer.

Qin Zheng1,2, Huaiyin Ding3, Lixue Wang2, Yu Yan1, Yuan Wan4, Yongxiang Yi5, Liang Tao6, Chuandong Zhu1.   

Abstract

Patients with non-small-cell lung cancer (NSCLC) frequently develop radioresistance, resulting in poor response to radiation and unfavourable prognosis. Early detection of radioresistance hence can guide the adjustment of treatment regimens in time. Exosomes are lipid bilayer-enclosed vesicles with sub-micrometer size that are released by various cells. Exosomes contain a tissue-specific signature wherein a variety of proteins and nucleic acids are selectively packaged. Growing evidence shows exosomes are involved in cancer pathophysiology and exosomes as the latest addition to the liquid biopsy portfolio have been used in cancer diagnosis. Compared to cell free RNA, exosomal lipid envelope can effectively protect RNA cargo against degradation. Therefore, exosomes may hold great promise for the identification of radioresistance. Here, we report six plasma exosomal miRNAs could be used to distinguish radioresistant NSCLC patients from radiosensitive NSCLC patients and to evaluate the prognosis of NSCLC. Samples were obtained from 52 NSCLC patients with or without radioresistance and 45 age-matched healthy volunteers. Exosomes in 1 ml plasma were isolated followed by extraction of small RNA. The expression levels of miRNAs were determined by quantitative real-time PCR. Potential miRNA markers were further evaluated in additional 52 NSCLC patients. We found exosomal miR-1246 and miR-96 are significantly overexpressed in NSCLC patients. Moreover, exosomal miR-96 in patients with radioresistant NSCLC is significantly higher than that of controls. Exosomal miR-96 also demonstrates a significant correlation with vascular invasion and poor overall survival. Altogether, our results indicate that exosomal miR-96 could be a non-invasive diagnostic and prognostic marker of radioresistant NSCLC.
Copyright © 2021 Qin Zheng et al.

Entities:  

Year:  2021        PMID: 33727921      PMCID: PMC7937465          DOI: 10.1155/2021/5893981

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


  31 in total

Review 1.  Lung cancer: diagnosis and management.

Authors:  Lauren G Collins; Christopher Haines; Robert Perkel; Robert E Enck
Journal:  Am Fam Physician       Date:  2007-01-01       Impact factor: 3.292

2.  Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Authors:  Salomon Manier; Chia-Jen Liu; Hervé Avet-Loiseau; Jihye Park; Jiantao Shi; Federico Campigotto; Karma Z Salem; Daisy Huynh; Siobhan V Glavey; Bradley Rivotto; Antonio Sacco; Aldo M Roccaro; Juliette Bouyssou; Stéphane Minvielle; Philippe Moreau; Thierry Facon; Xavier Leleu; Edie Weller; Lorenzo Trippa; Irene M Ghobrial
Journal:  Blood       Date:  2017-02-17       Impact factor: 22.113

3.  Radiotherapy is effective for a primary lung cancer invading the left atrium.

Authors:  Percy Lee; Amar U Kishan
Journal:  BMJ Case Rep       Date:  2012-07-19

Review 4.  miRNAs in cancer: approaches, aetiology, diagnostics and therapy.

Authors:  Cherie Blenkiron; Eric A Miska
Journal:  Hum Mol Genet       Date:  2007-04-15       Impact factor: 6.150

Review 5.  Reirradiation for locoregionally recurrent non-small cell lung cancer.

Authors:  Melissa A L Vyfhuis; Stephanie Rice; Jill Remick; Sina Mossahebi; Shahed Badiyan; Pranshu Mohindra; Charles B Simone
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 6.  Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.

Authors:  Sameera S Kumar; Kristin A Higgins; Ronald C McGarry
Journal:  Front Oncol       Date:  2017-09-04       Impact factor: 6.244

7.  miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.

Authors:  Mahrou Vahabi; Claudio Pulito; Andrea Sacconi; Sara Donzelli; Marco D'Andrea; Valentina Manciocco; Raul Pellini; Paola Paci; Giuseppe Sanguineti; Lidia Strigari; Giuseppe Spriano; Paola Muti; Pier Paolo Pandolfi; Sabrina Strano; Shahrokh Safarian; Federica Ganci; Giovanni Blandino
Journal:  J Exp Clin Cancer Res       Date:  2019-03-29

8.  miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma.

Authors:  Nanmu Yang; Jinxue Zhou; Qingjun Li; Feng Han; Zujiang Yu
Journal:  Cancer Cell Int       Date:  2019-02-20       Impact factor: 5.722

Review 9.  Exosomal miRNAs in hepatocellular carcinoma development and clinical responses.

Authors:  Shuangshuang Li; Jiping Yao; Mingjie Xie; Yanning Liu; Min Zheng
Journal:  J Hematol Oncol       Date:  2018-04-11       Impact factor: 17.388

10.  BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling.

Authors:  Rui Zuo; Minghan Liu; Yanqiu Wang; Jie Li; Wenkai Wang; Junlong Wu; Chao Sun; Bin Li; Ziwen Wang; Weiren Lan; Chao Zhang; Chunmeng Shi; Yue Zhou
Journal:  Stem Cell Res Ther       Date:  2019-01-15       Impact factor: 6.832

View more
  9 in total

Review 1.  Mechanism and clinical value of exosomes and exosomal contents in regulating solid tumor radiosensitivity.

Authors:  Huihui Sun; Rui Sun; Xing Song; Wendong Gu; Yingjie Shao
Journal:  J Transl Med       Date:  2022-04-28       Impact factor: 8.440

2.  Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.

Authors:  Wen Tian; Xianglin Yang; He Yang; Meiwen Lv; Xinran Sun; Baosen Zhou
Journal:  Cell Death Dis       Date:  2021-10-30       Impact factor: 9.685

Review 3.  Home and Away: The Role of Non-Coding RNA in Intracellular and Intercellular DNA Damage Response.

Authors:  Annabelle Shaw; Monika Gullerova
Journal:  Genes (Basel)       Date:  2021-09-23       Impact factor: 4.096

Review 4.  Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics.

Authors:  Zhenkun Xia; Bei Qing; Wei Wang; Linguo Gu; Hongzuo Chen; Yunchang Yuan
Journal:  Thorac Cancer       Date:  2021-11-04       Impact factor: 3.500

Review 5.  Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer.

Authors:  K Auxzilia Preethi; Sushmaa Chandralekha Selvakumar; Kehinde Ross; Selvaraj Jayaraman; Deusdedit Tusubira; Durairaj Sekar
Journal:  Mol Cancer       Date:  2022-02-16       Impact factor: 27.401

Review 6.  Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.

Authors:  Chan Shan; Yan Liang; Hongjing Cai; Fei Wang; Xinzhe Chen; Qikun Yin; Kun Wang; Yin Wang
Journal:  Mol Ther Oncolytics       Date:  2022-02-20       Impact factor: 7.200

Review 7.  Molecular Biomarkers in Cancer.

Authors:  Virinder Kaur Sarhadi; Gemma Armengol
Journal:  Biomolecules       Date:  2022-07-23

Review 8.  Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

Authors:  Chunyan Zhang; Caifang Sun; Yabin Zhao; Qiwen Wang; Jianlin Guo; Bingyu Ye; Guoying Yu
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

Review 9.  A Review on the Role of miR-1246 in the Pathoetiology of Different Cancers.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Mohammad Samadian
Journal:  Front Mol Biosci       Date:  2022-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.